Gene therapy targeting mitochondrial pathway in Parkinson’s disease
详细信息 查看全文
- 作者：Chi-Jing Choong ; Hideki Mochizuki
- 关键词：Gene therapy ; Mitochondrial dysfunction ; Parkinson’s disease ; Parkin ; PINK1 ; Alpha synuclein ; PGC ; 1 alpha
- 刊名：Journal of Neural Transmission
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：124
- 期：2
- 页码：193-207
- 全文大小：
- 刊物类别：Medicine
- 刊物主题：Neurology; Psychiatry; Pharmacology/Toxicology; Neurosciences;
- 出版者：Springer Vienna
- ISSN：1435-1463
- 卷排序：124
文摘
Parkinson’s disease (PD) presents a relative selective localization of pathology to substantia nigra and well-defined motor symptoms caused by dopaminergic degeneration that makes it an ideal target for gene therapy. Parallel progress in viral vector systems enables the delivery of therapeutic genes directly into brain with reasonable safety along with sustained transgene expression. To date, gene therapy for PD that has reached clinical trial evaluation is mainly based on symptomatic approach that involves enzyme replacement strategy and restorative approach that depends on the addition of neurotrophic factors. Mitochondrial dysregulation, such as reduced complex I activity, increased mitochondria-derived reactive oxygen species (ROS) production, ROS-mediated mitochondrial DNA damage, bioenergetic failure, and perturbation of mitochondrial dynamics and mitophagy, has long been implicated in the pathogenesis of PD. Many of mutated genes linked to familial forms of PD affect these mitochondrial features. In this review, we discuss the recent progress that has been made in preclinical development of gene therapy targeting the mitochondrial pathway as disease modifying approach for PD. This review focuses on the potential therapeutic efficacy of candidate genes, including Parkin, PINK1, alpha synuclein, PGC-1 alpha, and anti-apoptotic molecules.